Arena shares slip after report on serious adverse event in PAH study; Zealand partners with Eli Lilly;

@FierceBiotech: Popular yesterday: Gilead's sofosbuvir cures some of the toughest hepatitis C cases. Article | Follow @FierceBiotech

@JohnCFierce: Strange story: Low-profile Epirus lays claim to a PhIII success for Remicade biosimilar--backed by TPG, 5AM. News | Follow @JohnCFierce

@RyanMFierce: GoogleVentures bets on oral biologics from startup Rani Therapeutics. Report | Follow @RyanMFierce

@EmilyMFierce: Worm genome reveals possible drug targets. Item from FierceBiotech Research | Follow @EmilyMFierce

> Arena Pharmaceuticals ($ARNA) had a slight amendment to make to a recent 8-K filing. In a follow-up document, the troubled biotech noted that there had been a serious adverse event in its Phase I study of an experimental PAH drug. The amended filing also notes that investigators say that it is possible the event, a transient case of atrial fibrillation, is linked to the drug. The safety concerns took a 4% bite out of Arena's share price this morning. Filing

> Denmark's Zealand Pharma has forged an exclusive peptide drug research and development collaboration agreement with Eli Lilly ($LLY). The pact covers new drugs for Type 2 diabetes and obesity. Release

> San Francisco-based Nektar Therapeutics ($NKTR) is in line for a $25 million milestone payment in the event that the EMA accepts AstraZeneca's ($AZN) application for naloxegol. Story

Medical Device News

@FierceMedDev: Sign up to receive our new publication FierceDiagnostics in your inbox each Wednesday. Sign up here | Follow @FierceMedDev

@DamianFierce: St. Jude won a CE mark for its next-gen renal denervation device. News | Follow @DamianFierce

@MarkHFierce: There's a new brain cancer MRI Dx approach, and Harvard Medical School is partially behind it. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: Chip lined with human cells tests cancer drug delivery with minimal cost. FierceDrugDelivery article | Follow @MichaelGFierce

> Biotronik boosts MRI-safe options for pacemaker tech. Story

> LipoScience back to drawing board after FDA rebuff. Report

> HeartWare expands heart pump trial for destination therapy. More

Pharma News

@FiercePharma: Trending on our website: Top 20 orphan drugs by 2018. Special Report | Follow @FiercePharma

@CarlyHFierce: China's Simcere going private thanks to $495M buyout by chairman. ICYMI yesterday Follow @CarlyHFierce

> Novartis discount fails to persuade NICE on Afinitor in breast cancer. Article

> Bayer's Eylea challenges Novartis eye drug for share of new market. Report

Vaccines News

> Novartis begins shipping flu vaccines ahead of crucial season. Article

> Analysis finds most vaccines safe during breastfeeding. Report

> International Vaccine Institute inks Indian alliances. Item

> Herd immunity from GSK, Merck vaccines cutting hospitalizations. Story

> Low vaccination rate at megachurch linked to measles outbreak. Report

Pharma Manufacturing News

@EricPFierce: India's GRAF building nutraceutical plant. It sees the category as source of future revenue growth. Article | Follow @EricPFierce

> Injectable drugs to drive CMO growth. Story

> Fast-growing ICIG adds peptide manufacturer. Article

> Novartis OTC unit has another foul-up. Report

> DOJ files suit against plant with persistent issues. More

And Finally… New insights on hearing loss have inspired some fresh thinking on drugs that could prevent damage. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.